SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to assess effect of SHR6390 combined with anastrozole on
proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital